Natalie Byrne

3.4k total citations
11 papers, 125 citations indexed

About

Natalie Byrne is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Natalie Byrne has authored 11 papers receiving a total of 125 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 4 papers in Molecular Biology. Recurrent topics in Natalie Byrne's work include Lung Cancer Research Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Neutropenia and Cancer Infections (3 papers). Natalie Byrne is often cited by papers focused on Lung Cancer Research Studies (4 papers), Cancer therapeutics and mechanisms (3 papers) and Neutropenia and Cancer Infections (3 papers). Natalie Byrne collaborates with scholars based in United Kingdom, United States and Türkiye. Natalie Byrne's co-authors include John Park, M. Goldman, Bartolomé R. Celli, Richard Hepburn, David Halpin, Jonathan W. Goldman, Russell J. Diefenbach, Helen Rizos, Matteo S. Carlino and Elin S. Gray and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and The Oncologist.

In The Last Decade

Natalie Byrne

10 papers receiving 124 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Natalie Byrne United Kingdom 6 65 46 43 25 22 11 125
Jay Zeck United States 7 64 1.0× 25 0.5× 19 0.4× 13 0.5× 11 0.5× 10 101
Eleftheria Chorti Germany 6 101 1.6× 42 0.9× 11 0.3× 3 0.1× 45 2.0× 8 133
Masanari Hamaguchi Japan 8 80 1.2× 78 1.7× 20 0.5× 30 1.4× 19 139
Stefano Baldo Italy 4 36 0.6× 21 0.5× 15 0.3× 56 2.2× 24 1.1× 6 81
Verónica Pulito‐Cueto Spain 7 18 0.3× 65 1.4× 17 0.4× 3 0.1× 22 1.0× 24 121
Kinnosuke Matsumoto Japan 7 53 0.8× 65 1.4× 21 0.5× 10 0.5× 20 109
Michael Williamson Ireland 4 35 0.5× 110 2.4× 13 0.3× 1 0.0× 38 1.7× 6 161
Gabriella Lionetto Italy 7 95 1.5× 27 0.6× 20 0.5× 12 0.5× 24 142
Laura Bailey United Kingdom 5 28 0.4× 40 0.9× 28 0.7× 2 0.1× 27 1.2× 5 133

Countries citing papers authored by Natalie Byrne

Since Specialization
Citations

This map shows the geographic impact of Natalie Byrne's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie Byrne with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie Byrne more than expected).

Fields of papers citing papers by Natalie Byrne

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie Byrne. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie Byrne. The network helps show where Natalie Byrne may publish in the future.

Co-authorship network of co-authors of Natalie Byrne

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie Byrne. A scholar is included among the top collaborators of Natalie Byrne based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie Byrne. Natalie Byrne is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Park, John, Russell J. Diefenbach, Natalie Byrne, et al.. (2021). Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition. Cancers. 13(7). 1740–1740. 26 indexed citations
2.
Reinmuth, Niels, Marina Chiara Garassino, Dmytro Trukhin, et al.. (2021). P48.03 First-Line Durvalumab plus Platinum-Etoposide in ES-SCLC: Exploratory Analyses Based on Extent of Disease in CASPIAN. Journal of Thoracic Oncology. 16(3). S500–S500. 5 indexed citations
3.
Park, John, Russell J. Diefenbach, Natalie Byrne, et al.. (2020). Circulating tumor DNA (ctDNA) in patients (pts) with metastatic uveal melanoma (UM) treated with protein kinase C inhibitor (PKCi).. Journal of Clinical Oncology. 38(15_suppl). e22054–e22054. 2 indexed citations
4.
Paz‐Ares, Luis, Mikhail Dvorkin, Yuanbin Chen, et al.. (2020). Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.. Journal of Clinical Oncology. 38(15_suppl). 9002–9002. 33 indexed citations
5.
Chen, Yuanbin, Luis Paz‐Ares, Mikhail Dvorkin, et al.. (2020). First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC (CASPIAN): Impact of brain metastases on treatment patterns and outcomes.. Journal of Clinical Oncology. 38(15_suppl). 9068–9068. 12 indexed citations
6.
Nishio, Makoto, Jun Ho Ji, Katsuyuki Hotta, et al.. (2019). Overall survival with first-line durvalumab plus platinum-etoposide in patients with extensive-stage (ES)-SCLC in CASPIAN: Subgroup findings from Asia. Annals of Oncology. 30. ix197–ix198. 3 indexed citations
7.
Sabanathan, Dhanusha, et al.. (2017). Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?. The Oncologist. 22(12). 1470–1477. 6 indexed citations
8.
Planchard, David, Fabrice Barlési, Julien Mazières, et al.. (2014). Phase I Study of Tremelimumab (Trem) in Combination with Gefitinib (Gef) in Epidermal Growth Factor Receptor Mutant (Egfr-Mut) Non-Small Cell Lung Cancer (Nsclc). Annals of Oncology. 25. iv468–iv468. 1 indexed citations
9.
10.
Byrne, Natalie, et al.. (2012). The Rotaglide+ total knee replacement: a comparison of mobile versus fixed bearings. Knee Surgery Sports Traumatology Arthroscopy. 22(7). 1626–1631. 13 indexed citations
11.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay Zeck Breakdown of academic impact, for papers by Eleftheria Chorti Breakdown of academic impact, for papers by Masanari Hamaguchi Breakdown of academic impact, for papers by Stefano Baldo Breakdown of academic impact, for papers by Verónica Pulito‐Cueto Breakdown of academic impact, for papers by Kinnosuke Matsumoto Breakdown of academic impact, for papers by Michael Williamson Breakdown of academic impact, for papers by Gabriella Lionetto Breakdown of academic impact, for papers by Laura Bailey
Rankless by CCL
2026